Atypical EGFR lung cancer treatment after surgery or radiation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests zipalertinib, a targeted pill for people with non-small cell lung cancer that has an atypical EGFR gene change. It is given after standard treatment like surgery or radiation to help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage (IA2 to IIIC) or locally recurrent non-small cell lung cancer
- Your cancer has an unusual EGFR gene change (not the common Ex19del or L858R types), such as an exon 20 insertion or other rare changes
- You have completed all planned surgery and/or radiation, with no known remaining cancer
- If your cancer stage is IIA-IIIA, you must have had chemotherapy (unless you couldn't or refused)
- You did not get an immune checkpoint inhibitor within the last 12 weeks and are not planning to
- You have good overall health (ECOG 0 or 1) and adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking zipalertinib after lung cancer surgery can help prevent the cancer from coming back in people whose tumors have uncommon EGFR gene changes. It is a pill taken daily after recovery from surgery.
This trial gives access to an investigational drug called zipalertinib for people with a specific type of advanced lung cancer (EGFR exon 20 insertion) who have already tried chemotherapy. The goal is to see if the drug can help control the cancer when other treatments have stopped working.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
This trial tests whether a targeted therapy pill (EGFR-TKI) can control small spots in the other lung after surgery for early-stage lung cancer. It's for people whose cancer has a specific EGFR gene change and who still have suspicious spots in the opposite lung after one side is removed.
Hear when a new EGFR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.